Form 4 for BIIB Biogen
Accepted 2022-08-03 00:00:00 ET · period of report 2022-08-01 · accession 0001127602-22-020415 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-08-03 | 2022-08-01 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | F - Tax | $209.26 | -319 | 2,094 | -13% | -$66.8K |
| DM | 2022-08-03 | 2022-08-01 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | M - OptEx | $0.00 | +1,080 | 2,170 | +99% | $0 |
| D | 2022-08-03 | 2022-08-01 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | J - Other | $0.00 | -299 | 255 | -54% | $0 |
| DM | 2022-08-03 | 2022-08-01 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | M - OptEx | $0.00 | -1,080 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-08-01 | F | D | 243 | $209.26 | 2,676.29 | D | — | — | |
| 2 | Common | Common Stock | 2022-08-01 | M | A | 825 | $0.00 | 2,919.29 | D | — | — | |
| 3 | Common | Common Stock | 2022-08-01 | M | A | 255 | $0.00 | 2,170.29 | D | — | — | (F1) Includes 102.4003 shares acquired under the Biogen Inc. employee stock purchase plan. |
| 4 | Common | Common Stock | 2022-08-01 | F | D | 76 | $209.26 | 2,094.29 | D | — | — | |
| 5 | Derivative | Restricted Stock Unit | 2022-08-01 | J | D | 299 | $0.00 | 255 | D | $0.00 · — to 2022-08-01 | 299 Common Stock | (F3) This award was granted to the reporting person on August 1, 2019. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times (the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date)). |
| 6 | Derivative | Restricted Stock Unit | 2022-08-01 | M | D | 255 | $0.00 | 0 | D | $0.00 · — to 2022-08-01 | 255 Common Stock | (F3) This award was granted to the reporting person on August 1, 2019. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times (the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date)). |
| 7 | Derivative | Restricted Stock Unit | 2022-08-01 | M | D | 825 | $0.00 | 0 | D | $0.00 · — to 2022-08-01 | 825 Common Stock | (F4) This award was granted to the reporting person on August 1, 2019 and vested in full on August 1, 2022. |